1632-82-2

Basic information

• Product Name: 1-ethyl-4,5-diphenyl-1H-imidazole
• CAS NO: 1632-82-2
• Molecular Formula: C₁₇H₁₆N₂
• Molecular Weight: 248.3223
• Mol File: 1632-82-2.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 419.6°C at 760 mmHg
• Flash Point: 207.6°C
• Density: 1.05g/cm³
• Vapor Pressure: 7.31E-07mmHg at 25°C
• Refractive Index: 1.595
• CAS DataBase Reference: 1-ethyl-4,5-diphenyl-1H-imidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-ethyl-4,5-diphenyl-1H-imidazole(1632-82-2)
• EPA Substance Registry System: 1-ethyl-4,5-diphenyl-1H-imidazole(1632-82-2)

Safety Data

• Hazardous Substances Data: 1632-82-2(Hazardous Substances Data)

Usage

Chemical class

Imidazole class of organic compounds

Physical state

White to light yellow solid at room temperature

Uses

Pharmaceutical intermediate in the synthesis of various drugs and other bioactive compounds

Molecular weight

240.31 g/mol

Interaction with biological targets

Known for its ability to interact with enzymes, receptors, and other proteins

Importance in medicinal chemistry

Valuable building block in medicinal chemistry and drug discovery

Versatility

Versatile reagent in organic synthesis

Potential applications

Material science and other industrial processes

Upstream product

• 74-96-4 ethyl bromide 
• 668-94-0 4,5-diphenyl-1H-imidazole 
• 100-52-7 benzaldehyde 
• 119-53-9 2-hydroxy-2-phenylacetophenone 
• 134-81-6 benzil 

Relevant articles and documents

NHC gold halide complexes derived from 4,5-diarylimidazoles: Synthesis, structural analysis, and pharmacological investigations as potential antitumor agents

A series of novel neutral NHC gold halide complexes derived from 4,5-diarylimidazoles were synthesized, characterized, and analyzed for biological effects. High growth inhibitory effects in MCF-7 and MDA-MB 231 breast cancer as well as HT-29 colon cancer cell lines depended on the presence of the C4,C5-standing aromatic rings. Methoxy groups at these rings did not change the growth inhibitory properties, while F-substituents in the ortho-position (5d) increased the activity in MCF-7 and MDA-MB 231 cells. The substituents at the nitrogen atoms and the oxidation state of the metal play a subordinate role. The most active bromo[1,3-diethyl-4,5-bis(2-fluorophenyl)-1,3- dihydro-2H-imidazol-2-ylidene]gold(I) (5d) was distinctly more active than cisplatin. All complexes caused thioredoxin reductase (TrxR) inhibition (EC 50 = 374-1505 nM) distinctly lower than auranofin (EC50 = 18.6 nM) excluding this enzyme as main target. Because of the low nuclear content, a participation of DNA interaction on the mode of action is very unlikely. The missing ER binding and the missing correlation of growth inhibition and inactivation of COX enzymes exclude these targets, too. (Figure presented)